Retatrutide vs Tirzepatide
Both are incretin analogues studied in metabolic research. They differ in how many receptors they act on.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Receptor targets | GIP, GLP-1 and glucagon – triple agonist | GIP and GLP-1 – dual agonist |
| Class | Synthetic incretin analogue | Synthetic incretin analogue |
| Development status | In clinical trials by Eli Lilly (LY3437943) | Approved as a medicine in several countries under other brand names |
| Studied in | Metabolic research: energy turnover and glucose metabolism | Metabolic research: incretin signalling and glucose control |
| Variants we stock | 5 mg and 20 mg | See the product page for current variants |
What the difference means
The glucagon receptor is what sets them apart. Retatrutide acts on three receptors where Tirzepatide acts on two, and that difference is what the literature examines. Clinical results from the pharmaceutical companies' own candidates say nothing about the material sold here, and should not be read as if they did.
One receptor is the whole difference
Tirzepatide is a dual agonist: it acts on the GIP and GLP-1 receptors. Retatrutide acts on the same two, plus the glucagon receptor. That is why it is described as a triple agonist, and it is the one structural difference everything else hinges on.
Glucagon has historically been seen as the counterpart to insulin, so including that receptor in an agonist is not an obvious design decision. That is precisely why the research literature in the field takes an interest in it.
Different development status
Tirzepatide is approved as a medicine in several countries under its own brand names. Retatrutide (LY3437943) is still in clinical trials at Eli Lilly.
This is an important distinction to keep straight: the figures circulating about both come from the pharmaceutical companies' own candidates, manufactured and controlled within their supply chain. They say nothing about material bought as a research chemical, however well documented the batch is.
What this means for a research set-up
The difference in receptor profile is what makes them worth comparing at all. A set-up looking at the glucagon contribution will naturally use both, because one serves as a reference for the other.
Both are sold here exclusively for laboratory use, with a batch number and certificate of analysis for each batch.
Frequently asked questions
What is the difference between Retatrutide and Tirzepatide?
The number of receptors. Tirzepatide is a dual agonist for GIP and GLP-1. Retatrutide is a triple agonist and also acts on the glucagon receptor.
Is Retatrutide approved as a medicine?
No. Retatrutide is in clinical trials. Tirzepatide is approved in several countries, but that applies to the drug manufacturer's product – not to research chemicals.
Can I read Lilly's study results as information about this product?
No. Clinical data apply to the manufacturer's own candidate under their quality control and say nothing about material bought for research use.
All material is sold exclusively for research purposes and laboratory use. This page gives no dosing, instructions for use or health claims. Read more about safety and regulation.